{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:31:21Z","timestamp":1772569881428,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Non-bacterial osteomyelitis (NBO) is a rare chronic inflammatory bone disease related to immune system dysregulation. This disease belongs to a family of autoinflammatory diseases. It often coexists with other TNF-\u03b1-mediated immune-mediated diseases such as juvenile idiopathic arthritis (JIA) and inflammatory bowel diseases. Previously, interleukin-1-driven inflammation was described predominantly in monogenic cases of NBO, such as DIRA syndrome or Majeed syndrome. However, the association between NBO and JIA with systemic onset (soJIA) has not been described yet.<\/jats:p><jats:p>Herein, we describe the cases of two patients with soJIA with inflammatory bone lesions wherein canakinumab (anti-interleukin-1\u03b2 antibodies) caused remission.\n<\/jats:p><jats:sec><jats:title>Case descriptions<\/jats:title><jats:p>Patient 1\u2013A 6-month-old boy with typical soJIA suffered a destruction of the 7th to 9th ribs and the left pubic bone. Antibiotics, IVIG, and cyclosporine proved ineffective. Corticosteroids were effective, but due to the factor of corticosteroid dependence, which has some disadvantages, canakinumab with a dosage of 4\u2005mg\/kg was initiated every 4 weeks, which completely controlled the disease and allowed to taper corticosteroids.<\/jats:p><jats:p>Patient 2\u2014A 2-year-old girl developed chronic non-bacterial osteomyelitis of the 5th rib 2 months after taking corticosteroids prescribed for typical soJIA. She underwent surgical debridement removal, and several courses of antibiotics proved ineffective. She developed macrophage activation syndrome, following which anakinra was prescribed, which resulted in only temporary improvement. Therefore, this drug was switched to canakinumab, which caused corticosteroid-free remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is the first description of a rare association of soJIA with inflammatory bone lesions with the proven efficacy of IL-1 blockade. The association of two autoinflammatory conditions should indicate IL-1-driven mechanisms and a possible genetic basis. Follow-up genetic and functional studies are required to better understand the pathogenesis of such overlapping diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1163483","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:01:45Z","timestamp":1685509305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Juvenile idiopathic arthritis with systemic onset with inflammatory bone lesions: two case reports of patients successfully treated with canakinumab and experience gained from literature"],"prefix":"10.3389","volume":"11","author":[{"given":"Ekaterina I.","family":"Alexeeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana M.","family":"Dvoryakovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina T.","family":"Tsulukiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia M.","family":"Kondrateva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia M.","family":"Solomatina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gleb V.","family":"Kondratiev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luliia V.","family":"Peshekhonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail M.","family":"Kostik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/00006454-198710000-00009","article-title":"Chronic recurrent multifocal osteomyelitis: a noninfectious inflammatory process","volume":"6","author":"King","year":"1987","journal-title":"Pediatr Infect Dis J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11914-017-0405-9","article-title":"Chronic recurrent multifocal osteomyelitis (CRMO): presentation, pathogenesis, and treatment","volume":"15","author":"Hofmann","year":"2017","journal-title":". Curr Osteoporos Rep Curr Osteoporos Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clim.2018.04.011","article-title":"CD14\u2009+\u2009monocytes Contribute to inflammation in chronic nonbacterial osteomyelitis (CNO) through increased NLRP3 inflammasome expression","volume":"196","author":"Brandt","year":"2018","journal-title":"Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1546-0096-11-47","article-title":"Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO)","volume":"11","author":"Hedrich","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.clim.2015.09.013","article-title":"Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1beta expression and release","volume":"161","author":"Hofmann","year":"2015","journal-title":"Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1546-0096-12-30","article-title":"Deregulation of the IL-1\u03b2 axis in chronic recurrent multifocal osteomyelitis","volume":"12","author":"Scianaro","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00296-016-3466-7","article-title":"Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO)","volume":"36","author":"Hofmann","year":"2016","journal-title":"Rheumatol Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"155521","DOI":"10.1016\/j.cyto.2021.155521","article-title":"Cytokine profile in patients with chronic non-bacterial osteomyelitis, juvenile idiopathic arthritis, and insulin-dependent diabetes mellitus","volume":"143","author":"Kostik","year":"2021","journal-title":"Cytokine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/rheumatology\/key143","article-title":"The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the eurofever international registry","volume":"57","author":"Girschick","year":"2018","journal-title":"Rheumatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/acr.23462","article-title":"Chronic nonbacterial osteomyelitis\/chronic recurrent multifocal osteomyelitis study group and the childhood arthritis and rheumatology research alliance scleroderma, vasculitis, autoinflammatory and rare diseases subcommittee (2018) consensus treatment plans for chronic nonbacterial osteomyelitis refractory to nonsteroidal antiinflammatory drugs and\/or with active spinal lesions","volume":"70","author":"Zhao","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/1756-185X.12940","article-title":"Clinical and genetic association, radiological findings and response to biological therapy in seven children from Qatar with non-bacterial osteomyelitis","volume":"20","author":"Moussa","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1093\/rheumatology\/keab113","article-title":"A dysregulated interleukin-18-interferon-\u03b3-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis","volume":"60","author":"Hinze","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/BOR.0000000000000526","article-title":"Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment","volume":"30","author":"Yasin","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.210563","article-title":"Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the pharmachild registry","volume":"49","author":"Giancane","year":"2022","journal-title":"J Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/BOR.0000000000000098","article-title":"Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes","volume":"26","author":"Nirmala","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2332\/allergolint.55.337","article-title":"Tumor necrosis factor receptor-associated periodic syndrome mimicking systemic juvenile idiopathic arthritis","volume":"55","author":"Manki","year":"2006","journal-title":"Allergol Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41584-022-00797-1","article-title":"IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting","volume":"18","author":"Broderick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e94838","DOI":"10.1172\/jci.insight.94838","article-title":"Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist","volume":"2","author":"Garg","year":"2017","journal-title":"JCI Insight"},{"key":"B23","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups","volume":"36","author":"Feist","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s00296-011-2020-x","article-title":"Adult-onset still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation","volume":"32","author":"Rech","year":"2012","journal-title":"Rheumatol Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.rdc.2013.05.002","article-title":"Autoinflammatory bone diseases","volume":"39","author":"Stern","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3899\/jrheum.160690","article-title":"Anakinra in a cohort of children with chronic nonbacterial osteomyelitis","volume":"44","author":"Pardeo","year":"2017","journal-title":"J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/annrheumdis-2012-201818","article-title":"Efficacy of anti-IL-1 treatment in majeed syndrome","volume":"72","author":"Herlin","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12887-019-1617-1","article-title":"A case report of mevalonate kinase deficiency in a 14-month-old female with fevers and lower extremity weakness","volume":"19","author":"Coppola","year":"2019","journal-title":"BMC Pediatr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1902817","DOI":"10.1155\/2019\/1902817","article-title":"Deficiency of interleukin-1 receptor antagonist: a case with late onset severe inflammatory arthritis, nail psoriasis with onychomycosis and well responsive to Adalimumab therapy","volume":"2019","author":"Kutukculer","year":"2019","journal-title":"Case Reports Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1093\/rheumatology\/keaa119","article-title":"New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation","volume":"59","author":"Kuemmerle-Deschner","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12969-020-00454-5","article-title":"A case report of a novel compound heterozygous mutation in a Brazilian patient with deficiency of interleukin-1 receptor antagonist (DIRA)","volume":"18","author":"Mendon\u00e7a","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/1756-185X.14425","article-title":"Canakinumab treatment in a young girl with refractory chronic recurrent multifocal osteomyelitis associated with pyoderma gangrenosum","volume":"25","author":"Acierno","year":"2022","journal-title":"Int J Rheum Dis"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1163483\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:01:47Z","timestamp":1685509307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1163483\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":32,"alternative-id":["10.3389\/fped.2023.1163483"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1163483","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"article-number":"1163483"}}